Literature DB >> 15385504

Enhanced lung injury and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen-nitrogen species.

Elena N Atochina1, James M Beck, Angela M Preston, Angela Haczku, Yaniv Tomer, Seth T Scanlon, Trevor Fusaro, John Casey, Samuel Hawgood, Andrew J Gow, Michael F Beers.   

Abstract

Surfactant protein A (SP-A), a member of the collectin family, selectively binds to Pneumocystis carinii and mediates interactions between pathogen and host alveolar macrophages in vitro. To test the hypothesis that mice lacking SP-A have delayed clearance of Pneumocystis organisms and enhanced lung injury, wild-type C57BL/6 (WT) and SP-A-deficient mice (SP-A(-/-)) with or without selective CD4(+)-T-cell depletion were intratracheally inoculated with Pneumocystis organisms. Four weeks later, CD4-depleted SP-A-deficient mice had developed a more severe Pneumocystis infection than CD4-depleted WT (P. carinii pneumonia [PCP] scores of 3 versus 2, respectively). Whereas all non-CD4-depleted WT mice were free of PCP, intact SP-A(-/-) mice also had evidence of increased organism burden. Pneumocystis infection in SP-A-deficient mice was associated histologically with enhanced peribronchial and/or perivascular cellularity (score of 4 versus 2, SP-A(-/-) versus C57BL/6 mice, respectively) and a corresponding increase in bronchoalveolar lavage (BAL) cell counts. Increases in SP-D content, gamma interferon, interleukin-4, interleukin-5, and tumor necrosis factor alpha in BAL fluid occurred but were attenuated in PCP-infected SP-A(-/-) mice compared to WT mice. There were increases in total BAL NO levels in both infected groups, but nitrite levels were higher in SP-A(-/-) mice, indicating a reduction in production of higher oxides of nitrogen that was also reflected in lower levels of 3-nitrotyrosine staining in the SP-A(-/-) group. We conclude that despite increases in inflammatory cells, SP-A-deficient mice infected with P. carinii exhibit an enhanced susceptibility to the organism and attenuated production of proinflammatory cytokines and reactive oxygen-nitrogen species. These data support the concept that SP-A is a local effector molecule in the lung host defense against P. carinii in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385504      PMCID: PMC517574          DOI: 10.1128/IAI.72.10.6002-6011.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  68 in total

1.  Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop.

Authors:  J M Beck; M J Rosen; H H Peavy
Journal:  Am J Respir Crit Care Med       Date:  2001-12-01       Impact factor: 21.405

2.  Tumor necrosis factor alpha-mediated host defense against Pneumocystis carinii.

Authors:  A H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  1997-02       Impact factor: 6.914

Review 3.  Recurrent pneumothorax in AIDS patients with Pneumocystis pneumonia. A clinicopathologic report of three cases and review of the literature.

Authors:  M F Beers; M Sohn; M Swartz
Journal:  Chest       Date:  1990-08       Impact factor: 9.410

4.  Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia.

Authors:  T W Wright; F Gigliotti; J N Finkelstein; J T McBride; C L An; A G Harmsen
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon.

Authors:  J M Beck; H D Liggitt; E N Brunette; H J Fuchs; J E Shellito; R J Debs
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

6.  A sequential ultrastructural study of rat lungs infected with Pneumocystis carinii to investigate the appearances of the organism, its relationships and its effects on pneumocytes.

Authors:  P R Millard; A E Wakefield; J M Hopkin
Journal:  Int J Exp Pathol       Date:  1990-12       Impact factor: 1.925

7.  Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses.

Authors:  B A Garvy; J A Wiley; F Gigliotti; A G Harmsen
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

8.  120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A.

Authors:  P E Zimmerman; D R Voelker; F X McCormack; J R Paulsrud; W J Martin
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

9.  Altered surfactant function and structure in SP-A gene targeted mice.

Authors:  T R Korfhagen; M D Bruno; G F Ross; K M Huelsman; M Ikegami; A H Jobe; S E Wert; B R Stripp; R E Morris; S W Glasser; C J Bachurski; H S Iwamoto; J A Whitsett
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat.

Authors:  D S Phelps; T M Umstead; R M Rose; J A Fishman
Journal:  Eur Respir J       Date:  1996-03       Impact factor: 16.671

View more
  33 in total

1.  Effect of low doses of lipopolysaccharide prior to ozone exposure on bronchoalveolar lavage: Differences between wild type and surfactant protein A-deficient mice.

Authors:  Rizwanul Haque; Todd M Umstead; Kwangmi Ahn; David S Phelps; Joanna Floros
Journal:  Pneumon       Date:  2009

2.  Differences in Host Innate Responses among Coccidioides Isolates in a Murine Model of Pulmonary Coccidioidomycosis.

Authors:  Eric R G Lewis; Victoria R David; Adina L Doyle; Khadijeh Rajabi; Jeffrey A Kiefer; Patrick Pirrotte; Bridget M Barker
Journal:  Eukaryot Cell       Date:  2015-08-14

Review 3.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

4.  Early alveolar epithelial dysfunction promotes lung inflammation in a mouse model of Hermansky-Pudlak syndrome.

Authors:  Elena N Atochina-Vasserman; Sandra R Bates; Peggy Zhang; Helen Abramova; Zhenguo Zhang; Linda Gonzales; Jian-Qin Tao; Bernadette R Gochuico; William Gahl; Chang-Jiang Guo; Andrew J Gow; Michael F Beers; Susan Guttentag
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

5.  Dispensability of surfactant proteins A and D in immune control of Mycobacterium tuberculosis infection following aerosol challenge of mice.

Authors:  Maria P Lemos; John McKinney; Kyu Y Rhee
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

6.  Surfactant protein-D modulation of pulmonary macrophage phenotype is controlled by S-nitrosylation.

Authors:  Chang-Jiang Guo; Elena N Atochina-Vasserman; Elena Abramova; Ley Cody Smith; Michael F Beers; Andrew J Gow
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-08-14       Impact factor: 5.464

Review 7.  Cross-talk between pulmonary injury, oxidant stress, and gap junctional communication.

Authors:  Latoya N Johnson; Michael Koval
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

8.  Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages.

Authors:  Atsushi Mitsuhashi; Hisatsugu Goto; Takuya Kuramoto; Sho Tabata; Sawaka Yukishige; Shinji Abe; Masaki Hanibuchi; Soji Kakiuchi; Atsuro Saijo; Yoshinori Aono; Hisanori Uehara; Seiji Yano; Julie G Ledford; Saburo Sone; Yasuhiko Nishioka
Journal:  Am J Pathol       Date:  2013-03-14       Impact factor: 4.307

Review 9.  Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? (Review).

Authors:  Mudit Vaid; Joanna Floros
Journal:  Oncol Rep       Date:  2009-01       Impact factor: 3.906

10.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.